Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2016-01-05
- Target Recruit Count
- 2
- Registration Number
- NCT02058199
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 195
- Registration Number
- NCT02042534
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 127
- Registration Number
- NCT01989845
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study
- Conditions
- Interventions
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT01986192
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT01954238
- Locations
- 🇺🇸
PAREXEL Internatonal, Early phase clinical unit _Los Angeles, California, United States
Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2013-08-16
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 3700
- Registration Number
- NCT01923818
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5081
- Registration Number
- NCT01877915
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
- Conditions
- Interventions
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Cook County Health
- Target Recruit Count
- 33
- Registration Number
- NCT01747746
- Locations
- 🇺🇸
Cook County Hospital, Chicago, Illinois, United States
A Prospective Pharmacodynamic Study of Rivaroxaban
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 65
- Registration Number
- NCT01743898
- Locations
- 🇺🇸
Carolina Point II, Chapel Hill, North Carolina, United States
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 253
- Registration Number
- NCT01729871
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.